Is BTG plc a better buy than GlaxoSmithKline plc?

Should you buy growth star BTG plc (LON: BTG) or dividend dynamo GlaxoSmithKline (LSE: GSK)?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

British investing great Neil Woodford has said several times that the pharmaceutical industry is one of Britain’s great strengths, and is worthy of investing in. Prime candidates for your portfolio include AstraZeneca, GlaxoSmithKline (LSE: GSK) and Shire.

But a lesser known name, BTG (LSE: BTG) is actually one of the fastest growing pharma firms in the UK.

BTG’s latest results are impressive

But just who is BTG? Well it’s a company that develops speciality pharmaceuticals and interventional medicine in the areas of critical care, cancer and varicose veins. It also has a revenue stream from royalty payments on partnered products, and it has operations in Europe, North America and Australia.

BTG has just released its latest results. They are impressive, with a doubling of profits for the year ending 31 March. Pre-tax profits come in at £57.5m, with revenue forecast to increase by 8-15% next year.

So this is a company that has been growing earnings and profits rapidly. Earnings per share is expected to progress from 5.00p in 2013 to 23.14p in 2017. That is a rapid pace of growth, and justifies the firm’s high P/E rating. Small cap investors should take note.

How does it compare with a pension fund stalwart like GlaxoSmithKline? Well, Glaxo is a completely different kind of beast. It’s not fast growing, but aims to produce a consistent level of profitability each year. It is a far larger business. And its route to expansion is through emerging markets such as China.

GlaxoSmithKline looks to China for expansion

One thing that GlaxoSmithKline does have over BTG is a high dividend yield. The past year’s income was 5.49%, and the firm is likely to maintain or increase this payment into the future.

Glaxo also has faced a range of difficulties in recent years. Its much vaunted drugs pipeline has led to the launch of several new drugs, but none of these have been blockbusters — they turned out to be “me-too” treatments that are just additional options for doctors to prescribe. Meanwhile there have been a number of patent expiries.

However, the company hopes to expand in regions where healthcare spend is increasing rapidly, notably China, India and other emerging markets. And the firm has strengths in areas such as HIV treatments and vaccines, as well as a healthy consumer products arm.

Buy BTG for growth, but buy GlaxoSmithKline for income

So which of these businesses should you buy into? Well, I would say it depends entirely on what you are looking for. If you are a risk-taking growth investor on the look-out for the next big thing, then it has to be BTG. But if you are a more cautious investor who likes to accumulate and then reinvest those dividend cheques, then you should look no further than GlaxoSmithKline.

But I agree with Neil Woodford that Britain’s pharma industry is one that shows rich promise.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Prabhat Sakya has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »